Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

101.42 +2.65 (+2.68%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Incyte (NASDAQ:INCY) Reports Strong Q2

July 29, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of $1.57 per share...

Via StockStory

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 29, 2025

From Incyte

Via Business Wire

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

A Look at Incyte's Upcoming Earnings Report ↗

July 28, 2025

Via Benzinga

Incyte (INCY) Q2 Earnings: What To Expect

July 27, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday morning. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

July 24, 2025

From Incyte

Via Business Wire

1 Value Stock Worth Your Attention and 2 Facing Headwinds

July 24, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Topics Supply Chain

INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Attractive Valuation ↗

July 12, 2025

INCYTE CORP (NASDAQ:INCY) presents a value opportunity with strong profitability, financial health, and an undervalued forward P/E. Analysts expect earnings growth despite a slight revenue decline.

Via Chartmill

Incyte to Report Second Quarter Financial Results

July 10, 2025

From Incyte

Via Business Wire

3 Cash-Producing Stocks with Questionable Fundamentals

July 08, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 S&P 500 Stocks Skating on Thin Ice

July 03, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2025

From Incyte Corporation

Via Business Wire

Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)

June 29, 2025

Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season.

Via StockStory

Topics Artificial Intelligence

Top S&P500 movers in Friday's session ↗

June 27, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗

June 27, 2025

Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.

Via Stocktwits

Topics Intellectual Property

Uncover the latest developments among S&P500 stocks in today's session. ↗

June 26, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Thursday's session: top gainers and losers in the S&P500 index ↗

June 26, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Via Chartmill

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗

June 26, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Via Chartmill

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

June 26, 2025

From Incyte

Via Business Wire

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

June 20, 2025

From Incyte

Via Business Wire

INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential ↗

June 20, 2025

INCYTE CORP (NASDAQ:INCY) shows strong valuation, profitability, and financial health, making it an interesting pick for value investors. The stock trades at a discount to peers with solid growth...

Via Chartmill

3 Low-Volatility Stocks with Questionable Fundamentals

June 20, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

June 18, 2025

From Incyte

Via Business Wire

3 Unpopular Stocks in Hot Water

June 17, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

June 16, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Monday?

Via Chartmill

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses ↗

June 16, 2025

Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development.

Via Benzinga

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

June 16, 2025

Via Benzinga

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗

June 16, 2025

Stifel also upgraded the stock to ‘Buy’ with a $107 price target.

Via Stocktwits

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15, 2025

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.